teaser
Orion Corporation has submitted a marketing authorisation application for combined budesonide-formoterol formulation of the Easyhaler® product family in Europe.
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
Orion applies for approval in EU through decentralised procedure. The review process will commence once all involved member states have validated the application.
